YH42946

PreclinicalSmall molecule

YH42946 is one of 7 small molecule programs targeting NSCLC (Non-small Cell Lung Cancer). It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

NSCLC (non-Small Cell Lung Cancer)Recruiting

NSCLC (non-Small Cell Lung Cancer)Preclinical

Recruiting

Competition

Competitive Landscape

7 competitors in NSCLC (non-Small Cell Lung Cancer)

#DrugCompanyPhaseTrials

Gavreto

RRigel Pharmaceuticals

Approved

1 2

Rasonque

Revolution Medicines

Phase 3

1 3

Beyfortus

BeiGene

Phase 2

1 4

PD-1/PD-L1 Inhibitor

SSecond Affiliated Hospital of Soochow University

Phase 3

1 5

Surufatinib

HHutchison Medipharma Limited

Phase 2

1 6

Concurrent Chemotherapy

SSun Yat-sen University

Phase 2

1 7

YH42946

YYuhan Corporation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

PreclinicalRecruiting

NSCLC (non-Small Cell Lung Cancer)

NCT06616766

Clinical

Trials by Indication[1]

NSCLC (Non-small Cell Lung Cancer)1 trial

A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion

Recruiting·YYuhan Corporation·Preclinical·NCT06616766·201 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for YH42946. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — YH42946 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for YH42946. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yuhan Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: YYuhan Corporation

YH42946

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

NSCLC (Non-small Cell Lung Cancer)1 trial

References

Drug Info

Quick Facts

Related News